<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00226304</url>
  </required_header>
  <id_info>
    <org_study_id>050246</org_study_id>
    <secondary_id>05-CC-0246</secondary_id>
    <nct_id>NCT00226304</nct_id>
  </id_info>
  <brief_title>Evaluation of Brain Lesions in HIV-infected Patients for Diagnosis of Primary Central Nervous System Lymphoma</brief_title>
  <official_title>The Evaluation of Focal Contrast-Enhancing Brain Lesions in HIV-Infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institutes of Health Clinical Center (CC)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      This study will evaluate the usefulness of two tests in quickly distinguishing whether a&#xD;
      patient with HIV infection and focal brain lesions (an injury in a specific area of the&#xD;
      brain) has a rare type of cancer called primary central nervous system lymphoma (PCNSL), or a&#xD;
      parasitic infection called toxoplasmic encephalitis.&#xD;
&#xD;
      Toxoplasmic encephalitis is caused by a parasite and can be treated with antibiotics. PCNSL&#xD;
      (lymphoma of the brain or spinal cord) must be definitively diagnosed with a brain biopsy&#xD;
      (removal of a small piece of brain tissue), and the treatment is radiation therapy and&#xD;
      chemotherapy.&#xD;
&#xD;
      The tests under study for diagnosing PCNSL or toxoplasmic encephalitis are measurement of&#xD;
      Epstein Barr virus (EBV) DNA in cerebrospinal fluid (CSF) and FDG-PET scan of the brain. EBV&#xD;
      is often found in the CSF of people with PCNSL. The study also will compare the accuracy of&#xD;
      two imaging techniques-TI-SPECT and FDG-PET-in distinguishing between toxoplasmosis and&#xD;
      PCNSL.&#xD;
&#xD;
      Patients 18 years of age and older who have HIV infection and at least one focal brain lesion&#xD;
      without a prior history of PCNSL or toxoplasmic encephalitis may be eligible for this study.&#xD;
      Each candidate is screened with a medical history, physical examination, blood and urine&#xD;
      tests and MRI scans of the brain.&#xD;
&#xD;
      Upon entering the study, all participants take medication to treat toxoplasmic encephalitis.&#xD;
      They undergo lumbar puncture (spinal tap) to obtain CSF for analysis, an FDG-PET scan, and a&#xD;
      201TI-SPECT scan. For the PET scan, a radioactive substance is injected into an arm, followed&#xD;
      by scanning in a doughnut-shaped machine similar to a CT scanner. SPECT is similar to PET but&#xD;
      uses a different radioactive tracer, and the patient lies on a table while the SPECT camera&#xD;
      rotates around the patient's head. Patients whose test results indicate a low risk for&#xD;
      lymphoma continue antibiotic therapy for toxoplasmosis. They have repeat MRI scans around 4,&#xD;
      7, and 14 days after starting the drug to monitor the response to therapy. Antiretroviral&#xD;
      therapy is initiated in patients who are not already on such a regimen.&#xD;
&#xD;
      Patients whose test results indicate a high risk for PCNSL have a CT scan to look for&#xD;
      evidence of lymphoma elsewhere in the body and are referred for consultation with a&#xD;
      neurosurgeon to discuss undergoing a brain biopsy. The brain biopsy is done in the operating&#xD;
      room under general anesthesia. A small cut is made in the scalp and a small opening is made&#xD;
      in the skull over the area of the brain to be biopsied. A needle is placed in the opening in&#xD;
      the skull and, guided by CT or MRI, moved to the abnormal area of the brain, where a small&#xD;
      piece of tissue is removed for study under a microscope.&#xD;
&#xD;
      Patients found to have toxoplasmosis are discharged from the hospital to the care of their&#xD;
      primary care physician after they are getting better and are tolerating all their&#xD;
      medications. They return to NIH for follow-up visits about 4 weeks, and 6 months after&#xD;
      discharge.&#xD;
&#xD;
      Patients found to have lymphoma are referred to the National Cancer Institute for screening&#xD;
      for enrollment in a treatment protocol. Patients who are not eligible for a treatment&#xD;
      protocol are referred back to their primary care physician or for another NIH treatment&#xD;
      protocol, if one is available. Patients with lymphoma are seen at the NIAID outpatient clinic&#xD;
      for follow-up visits and laboratory examinations every 3 months for 2 years.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Epstein Barr Virus (EBV)-associated primary central nervous system lymphoma (PCNSL) remains a&#xD;
      major problem among AIDS patients. The clinical presentation is often clinically&#xD;
      indistinguishable from toxoplasmic encephalitis. The method of choice for establishing the&#xD;
      definitive diagnosis is brain biopsy. This procedure can be associated with a significant&#xD;
      morbidity and mortality, and therefore less invasive means of diagnosing cerebral mass&#xD;
      lesions have been studied.&#xD;
&#xD;
      Currently, an accepted standard of care for HIV-infected patients that present with signs and&#xD;
      symptoms of focal brain lesions is to empirically treat for toxoplasmic encephalitis. Brain&#xD;
      biopsy is often deferred until there is demonstration of lack of clinical response or&#xD;
      progression on empiric therapy. As a result, treatment initiation is frequently delayed.&#xD;
      During this time it is not unusual for further clinical deterioration to occur before&#xD;
      appropriate therapies can be initiated. Frequently, the alternative approaches then become a&#xD;
      question of appropriate palliation rather than curative intent therapy.&#xD;
&#xD;
      Less invasive diagnostic tests to assist in the diagnosis have been investigated. Based on&#xD;
      the finding that essentially 100% of HIV-related PCNSL are EBV-associated, the detection of&#xD;
      EBV DNA by PCR amplification in the cerebrospinal fluid (CSF) has demonstrated clinical&#xD;
      usefulness in the diagnosis, as has the use of neuroradiologic imaging to detect the&#xD;
      malignancy. Prior studies have demonstrated that the use of a combination of neuroradiologic,&#xD;
      immunologic, and clinical variables in the workup of focal brain lesions in HIV-infected&#xD;
      patients to be quite accurate in identifying patients in need of brain biopsy, but a&#xD;
      diagnostic algorithm that incorporates the combination of the most sensitive and specific&#xD;
      tests in a timely manner has not yet been explored.&#xD;
&#xD;
      This study seeks to evaluate an algorithm for the workup of HIV infected patients with focal&#xD;
      brain lesions so as to expedite the diagnosis and subsequent treatment of PCNSL. The goals of&#xD;
      the study are to 1) determine the specificity, sensitivity, and positive predictive value of&#xD;
      a diagnostic algorithm that entails the use of the combination of EBV detection in the CSF&#xD;
      and FDG-PET scanning to diagnose PCNSL; 2) evaluate the time to response to anti-toxoplasmic&#xD;
      encephalitis therapy, and 3) evaluate the sensitivities and specificities of FDG-PET and&#xD;
      (201)Tl-SPECT scanning in identifying PCNSL. Up to one hundred HIV-infected patients with&#xD;
      history of at least one focal brain lesion will be screened for enrollment. All patients will&#xD;
      be treated empirically for toxoplasmic encephalitis until an alternative diagnosis is&#xD;
      confirmed. All enrolled patients will be treated concurrently with antiretroviral therapy.&#xD;
      Patients identified to have PCNSL will be referred to the NCI Treatment of PCNSL Protocol for&#xD;
      further treatment if the study is open for enrollment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 20, 2005</start_date>
  <completion_date>April 15, 2009</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <enrollment>120</enrollment>
  <condition>HIV Infections</condition>
  <condition>Lymphoma, AIDS-Related</condition>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
        Adult (18 years old or older) HIV-infected patient&#xD;
&#xD;
        HIV infected by OraQuick rapid test using saliva, venipuncture whole blood, or fingerstick&#xD;
        whole blood; or by reactive ELISA and Western Blot as determined by an outside&#xD;
        CLIA-approved laboratory facility or by NIH Clinical Pathology Laboratory or SAIC-Frederick&#xD;
        Inc Monitoring Laboratory. HIV infection as determined by an outside CLIA-approved&#xD;
        laboratory facility will be verified by a standard HIV-1 ELISA with Western Blot&#xD;
        confirmation prior to brain biopsy.&#xD;
&#xD;
        Evidence of contrast-enhancing focal brain lesion(s) as seen on MRI or CT&#xD;
&#xD;
        Willingness to give informed consent and provided by Durable Power of Attorney. In the&#xD;
        event that no Durable Power of Attorney has been designated and the patient is unable to do&#xD;
        so, the NIH Ethics Committee will be consulted. All patients must designate a Durable Power&#xD;
        of Attorney in order to participate in the study.&#xD;
&#xD;
        Willingness to undergo the procedures involved in the diagnostic evaluation: lumbar&#xD;
        puncture, FDG-PET scan, 201Tl-SPECT scan, and brain biopsy.&#xD;
&#xD;
        Permit the storage of blood, CSF, and tissue samples for future research use&#xD;
&#xD;
        Willingness to undergo HLA testing&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
        Previous PCNSL&#xD;
&#xD;
        History of prior malignancy other than PCNSL unless in remission for 1 year or longer;&#xD;
        non-melanoma skin cancer and Kaposi's sarcoma excepted&#xD;
&#xD;
        History of previous diagnosis of toxoplasmic encephalitis or other CNS infection causing&#xD;
        focal contrast-enhancing brain lesions&#xD;
&#xD;
        Pregnancy or currently breast feeding&#xD;
&#xD;
        Have any other condition that the research team considers a contraindication to&#xD;
        participating in the study, e.g. severe cardiac, renal, or pulmonary dysfunction.&#xD;
&#xD;
        Weight greater than 400 lb for PET and 500 lb for SPECT (limit of the gantry).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Cot√© TR, Manns A, Hardy CR, Yellin FJ, Hartge P. Epidemiology of brain lymphoma among people with or without acquired immunodeficiency syndrome. AIDS/Cancer Study Group. J Natl Cancer Inst. 1996 May 15;88(10):675-9.</citation>
    <PMID>8627644</PMID>
  </reference>
  <reference>
    <citation>Basso U, Brandes AA. Diagnostic advances and new trends for the treatment of primary central nervous system lymphoma. Eur J Cancer. 2002 Jul;38(10):1298-312. Review.</citation>
    <PMID>12091059</PMID>
  </reference>
  <reference>
    <citation>MacMahon EM, Glass JD, Hayward SD, Mann RB, Becker PS, Charache P, McArthur JC, Ambinder RF. Epstein-Barr virus in AIDS-related primary central nervous system lymphoma. Lancet. 1991 Oct 19;338(8773):969-73.</citation>
    <PMID>1681341</PMID>
  </reference>
  <verification_date>April 15, 2009</verification_date>
  <study_first_submitted>September 23, 2005</study_first_submitted>
  <study_first_submitted_qc>September 23, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2005</study_first_posted>
  <last_update_submitted>June 30, 2017</last_update_submitted>
  <last_update_submitted_qc>June 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2017</last_update_posted>
  <keyword>Focal Brain Lesions</keyword>
  <keyword>AIDS</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>EBV</keyword>
  <keyword>FDG-PET</keyword>
  <keyword>HIV Infection</keyword>
  <keyword>Brain Lesion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, AIDS-Related</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

